[Table_StockInfo] 买入 2024年 04月 28日 （维持） 证券研究报告•2023年报&2024年一季报点评 当前价： 19.95元 百润股份（002568） 食品饮料 目标价： 24.18元（6个月） 高基数下收入稳健增长，净利率短期承压 投资要点 西南证券研究发展中心 [T ab事le件_S：u公mm司a发ry布] 2023年报及 2024年一季报，2023年实现营业收入32.6亿元 [分Ta析bl师e_：Au朱th会or振] （+25.9%），实现归母净利润8.1亿元（+55.3%）；2024Q1实现营业收入8亿 执业证号：S1250513110001 元（+5.5%），实现归母净利润1.7亿元（-9.8%）。 电话：023-63786049  鸡尾酒延续稳健增长，品类组合策略清晰。1、分品类看，2023 年鸡尾酒、食 邮箱：zhz@swsc.com.cn 用香精分别实现收入28.8亿元（+27.8%）、3.2亿元（+13.2%）。1）鸡尾酒业 分析师：夏霁 务品类组合策略清晰，口味及包装升级、季节限定等稳固增长。强爽起量以来， 执业证号：S1250523070006 公司加大投 ...

Investment Rating - The report maintains a "Buy" investment rating for the company, suggesting a positive outlook for the stock over the next six months [2][17]. Core Insights - The company achieved a revenue of 780 million yuan in 2023, marking a 100% year-on-year growth, and a net profit of 300 million yuan, which is a 174.6% increase year-on-year [1][3]. - The company is focusing on building its own brand "Wei Yi Mei" and enhancing its product offerings, which has led to significant sales growth [1]. - The company has restructured its collagen product channels primarily targeting private medical institutions, resulting in a sales team of 135 people covering approximately 2,000 end-user institutions by the end of 2023 [1]. Financial Performance - In Q4 2023, the company reported a revenue of 260 million yuan, up 89.7% year-on-year, and a net profit of 110 million yuan, reflecting a 176.1% increase year-on-year [1]. - For Q1 2024, the company achieved a revenue of 230 million yuan, a 76.1% increase year-on-year, and a net profit of 100 million yuan, which is a 135.7% increase year-on-year [1]. - The company plans to continue expanding its market share and product range, with projected net profits for 2024-2026 estimated at 460 million, 640 million, and 870 million yuan respectively, corresponding to PE ratios of 31, 22, and 16 times [2][3]. Revenue Breakdown - In 2023, the company's revenue from medical devices, functional skincare products, and raw materials was 680 million, 80 million, and 20 million yuan respectively, with year-on-year growth rates of 122.7%, 12.0%, and 42.9% [17]. - Revenue from different regions showed significant growth, with North China and East China achieving revenue of 280 million yuan each, reflecting year-on-year increases of 69.3% and 161.2% respectively [17]. Profitability Metrics - The gross margin for Q1 2024 reached 91.9%, an increase of 2.0 percentage points year-on-year, marking a historical high for the company [18]. - The net profit margin for Q1 2024 was 45.0%, up 11.5 percentage points year-on-year, benefiting from improved gross margins and reduced expense ratios [18].

[ 2T 0a 2b 4l 年e_S 0t 4o 月ckI 2n 5f 日o] 证券研究报告•2023年报&2024年一季报点评 当前价： 30.56元 百洋医药（301015） 医药生物 目标价： ——元（6个月） 持续聚焦主业，品牌运营稳健增长 投资要点 西南证券研究发展中心 [T a事ble件_S：u公mm司a发ry布] 2023年年报及 2024年一季报。2023年公司实现收入75.6亿 [分Ta析bl师e_：Au杜th向or阳] 元（+0.7%）；实现归母净利润 6.6亿元（+29.6%）；扣非归母净利润 6.4亿元 执业证号：S1250520030002 （+25.1%）。2024Q1公司实现收入 16.6亿元（-1.5%）；实现归母净利润 1.7 电话：021-68416017 亿元（+35.6%）；扣非归母净利润1.7亿元（+30.7%）。 邮箱：duxy@swsc.com.cn  2023 年业绩稳健增长。分业务看：1）品牌运营业务：公司的核心业务品牌运 营业务实现收入44亿元（+18.9%），若还原两票制业务后计算，品牌运营业务 [相Tab对le指_Q数u表ot现eP ic] 实现营业 ...

| --- | --- | --- | --- | --- | --- | |-------|----------------------------|----------------------|--------------|-------------|----------------------| | 区域 | [Table_SalesPerson] 姓名 | 职务 | 座机 | 手机 | 邮箱 | | | 蒋诗烽 | 总经理助理、销售总监 | 021-68415309 | 18621310081 | jsf@swsc.com.cn | | | 崔露文 | 销售副总监 | 15642960315 | 15642960315 | clw@swsc.com.cn | | | 谭世泽 | 高级销售经理 | 13122900886 | 13122900886 | tsz@swsc.com.cn | | | 汪艺 | 高级销售经理 | 13127920536 | 13127920536 | wyyf@swsc.com.cn | | | 李煜 | 高级销售经理 | 18801732511 | 18801732511 ...

本报告 须注明出处为"西南证券"，且不得对本报告及附录进行有悖原意的引用、删节和修改。未经授权刊载或者转发本报告 及附录的，本公司将保留向其追究法律责任的权利。 西南证券机构销售团队 请务必阅读正文后的重要声明部分 同庆楼（605108）2023 年报及 2024 年一季报点评 | --- | --- | --- | --- | --- | --- | |-------|--------|--------------------|-------------|-------------|----------------------| | | 张鑫 | 高级销售经理 | 15981953220 | 15981953220 | zhxin@swsc.com.cn | | | 王一菲 | 销售经理 | 18040060359 | 18040060359 | wyf@swsc.com.cn | | | 王宇飞 | 销售经理 | 18500981866 | 18500981866 | wangyuf@swsc.com | | | 路漫天 | 销售经理 | 18610741553 | 18610741553 | lmtyf ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 20% in the next six months [16][26]. Core Insights - The company has shown steady revenue growth, with a reported revenue of 57.8 billion yuan in Q1 2024, reflecting an 8.3% year-over-year increase, and a net profit of 3 billion yuan, up 15% [38]. - The wholesale business continues to dominate, contributing 81.8% of total revenue, while the retail and industrial segments also show significant growth [1]. - The company is expanding its market presence in the Guangxi region and enhancing its product offerings, particularly in traditional Chinese medicine [16]. Financial Performance Summary - For 2023, the company achieved a total revenue of 208.1 billion yuan, a 9.2% increase, and a net profit of 8.5 billion yuan, up 21.1% [38]. - The forecast for 2024-2026 indicates continued growth, with expected net profits of 10.2 billion yuan, 12.4 billion yuan, and 14.9 billion yuan, corresponding to year-over-year growth rates of 20.2%, 21.1%, and 20.5% respectively [26][44]. - The wholesale segment is projected to grow at rates of 9%, 8%, and 8% over the next three years, while the retail segment is expected to grow at 20%, 15%, and 15% [18][43]. Business Segment Analysis - The wholesale business generated 47 billion yuan in Q1 2024, a 6.2% increase, while the retail segment achieved 7.8 billion yuan, growing by 20% [1]. - The industrial segment reported 2.7 billion yuan in revenue, reflecting an 8.7% increase, with a stable gross margin of 45% expected through 2026 [5][44]. - The company has successfully opened 105 new stores in 2023, increasing its total to 814, with a focus on enhancing its competitive edge in the retail market [27].

Investment Rating - The investment rating for the company is "Hold" [16] Core Views - The company reported a significant decline in revenue and net profit for 2023, with revenue at 1.92 billion yuan, down 22.8% year-on-year, and net profit attributable to shareholders at 440 million yuan, down 50.9% year-on-year. However, in Q1 2024, the company saw a revenue increase of 30% year-on-year to 740 million yuan and a net profit increase of 44.9% to 285 million yuan [1][11] - The company is undergoing internal restructuring and cost-cutting measures, which have started to show positive results, as evidenced by a net profit margin increase to 38.2% in Q1 2024 [1][11] - The company has developed a comprehensive product line in the nephrology sector, which includes three series of blood purification products, and has adjusted pricing strategies to enhance market competitiveness [1][11] - The company is actively expanding its overseas market presence, with its blood purification devices generating 230 million yuan in revenue, a 19.26% increase year-on-year [1][11] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 1.92 billion yuan and a net profit of 440 million yuan, with a significant decline in both metrics compared to the previous year. In Q1 2024, revenue was 740 million yuan, showing a 30% increase year-on-year, while net profit reached 285 million yuan, up 44.9% [1][11] - The company’s gross margin for Q1 2024 was 78.7%, slightly down due to price reductions in its HA130 product line [1][11] Product Development - The company has established a three-product system in the nephrology field, including HA series, KHA series, and pHA series blood purification devices. The HA series has been in clinical use for 20 years and is widely adopted across over 6000 hospitals [1][11] - The KHA series, aimed at uremia treatment, saw a revenue increase of 79.5% in 2023, while the pHA series was launched in November 2023 and is currently undergoing trials in multiple hospitals [1][11] Market Expansion - The company’s blood purification equipment sales reached 230 million yuan, with the DX-10 blood purification machine being a key product, generating 227 million yuan in revenue, a 22.64% increase year-on-year. The DX-10 is now used in approximately 1800 hospitals nationwide [1][11] - The company has successfully entered 92 countries with its products, and 13 countries have included its products in their medical insurance systems [1][11] Profit Forecast - The company forecasts net profits of 800 million yuan, 1.03 billion yuan, and 1.31 billion yuan for 2024, 2025, and 2026, respectively, indicating a recovery trajectory following the restructuring efforts [1][11]

[ T able_StockInfo] 2024 年 04 月 26 日 证券研究报告•2023 年年报点评 买入 （维持） 当前价：21.25 元 华统股份（002840）食品饮料 目标价：25.53 元（6 个月） [Table_Summary 业绩总结：公司发布 ] 2023年年度报告。公司 2023年全年实现营收 85.8亿元， 同比-9.2%；实现归母净利润-6.0亿元，同比-789.3%。其中，Q4实现营业收入 24.1 亿元，同比-20.4%；归母净利润-2.5 亿元，同比-681.8%。 点评：生猪出栏维持高增，猪价低迷导致亏损。公司利润同比出现大幅下降主 要原因系随着公司猪场产能持续投产，出栏量迅速增长但受供求关系影响生猪 价格持续低位运行。2023年公司共计销售生猪 230.3万头，同比+91.1%，；销 售均价 15.0元/公斤，同比-23.6%。公司 2023 年屠宰生猪 448.17 万头， 同 比增长 29.38% 。报告期内饲料加工业务目前产能接近 80 万吨；家禽销售数 量约 1131.24 万羽，屠宰量约1101.4 万羽。 能繁母猪进一步加速去化，养殖行业反转成确定性趋势。 ...

Investment Rating - The report assigns a "Buy" rating for Runze Technology (300442) with a target price of 38.7 CNY over the next six months [1]. Core Insights - Runze Technology reported a robust revenue growth of 60.3% year-on-year in 2023, reaching 4.35 billion CNY, with a net profit of 1.76 billion CNY, up 47% [2][19]. - The company is expanding its AIDC business, which is becoming a new growth driver alongside its established IDC operations [2][11]. - The data center industry is projected to continue growing, driven by digital transformation and AI technology, with a market size nearing 200 billion CNY in 2022 and a compound annual growth rate (CAGR) of 30.69% over the past three years [2][19]. Summary by Sections 1. Business Overview - Runze Technology focuses on IDC and AIDC businesses, establishing a comprehensive layout across six major regions in China, with plans for approximately 61 intelligent computing centers and 320,000 cabinets [2][11][19]. - The company has successfully completed asset restructuring and is enhancing its data center construction investments [11]. 2. Financial Analysis - The company achieved a net profit margin of 40.4% in 2023, despite a slight decline of 8.4% year-on-year [2][21]. - The revenue from IDC business is expected to grow steadily, while AIDC is anticipated to see a significant increase due to rising demand for AI computing power [28][30]. - R&D expenses have increased to 101.24 million CNY in 2023, reflecting a commitment to technological advancement [25][27]. 3. Earnings Forecast and Valuation - The forecasted earnings per share (EPS) for 2024-2026 are 1.29 CNY, 1.67 CNY, and 2.25 CNY, respectively, with a projected compound growth rate of 29.93% for net profit [3][30]. - The report suggests a valuation of 30 times earnings for 2024, leading to a target price of 38.7 CNY [3][30].

新增订单成绩亮眼，氢能布局进展迅速 深化改革持续推进，盈利能力逐步修复。2023年，公司毛利率、净利率分别为 15.9%，1.3%，同比分别+0.4pp、+0.4pp；期间费用率为 14.4%，同比+0.5pp。 24Q1，公司毛利率、净利率分别为 14.5%、1.9%，同比分别+0.3pp、+1.4pp； 期间费用率为 13.0%，同比+2.0pp。公司坚持深化改革，优化管理，盈利能力 有望进一步改善。 盈利预测与投资建议。预计公司 2024-2026年归母净利润分别为 1.5、2.3、3.3 亿元，对应 EPS 为 0.16、0.24、0.35元，对应当前股价 PE 为 40、26、18倍， 未来三年归母净利润复合增速为 54%，维持"持有"评级。 [ T able_StockInfo] 2024 年 04 月 26 日 证券研究报告•2023 年报&2024 一季报点评 持有 （维持） 当前价：6.22 元 石化机械（000852）机械设备 目标价：——元（6 个月） [Table_Summary 事件：公司发布] 2023年年报和 2024年一季报。2023年实现营收 84.0亿，同 比+8.3%；实 ...